Revolutionizing breast cancer detection
Breast cancer is the most diagnosed cancer in women in the United States and the second leading cause of cancer death in American women.1 It is also treatable if detected early enough.
While there are various cancer detection modalities available, current breast CT imaging devices fail to expose as much as 35% of breast cancers, and that number increases to 70% for women who have dense breasts.
Current Breast Imaging Technology
Mammography is currently the most common device used to detect breast cancer. Though there is evidence that mammograms decrease breast cancer mortality in women aged 50 to 69 years, there is also evidence to show that they tend to lead to overdiagnosis and unnecessary procedures.
Compounding on the issue of overdiagnosis, mammograms have the potential to:
- Increase women’s anxiety towards exams.
- Cause potential delay in cancer diagnosis due to false negatives.
- Cause a great deal of pain and discomfort for women due to compression of the breasts.
KBCT Vs. Other Forms of Breast Imaging
Other forms of breast imaging have characteristics used to mitigate the problems arising from mammography, but few can provide both early detection and accurate diagnosis.
Koning Breast Computed Tomography (KBCT) produces high-contrast real 3D images of the breast with exceptional spatial resolution, no painful compression, in a rapid 10-second exposure, and at radiation levels in the range of diagnostic mammograms. Our technology detects stage 0 and stage 1 cancers, finding tumors as small as 2 mm and calcifications as small as 200 microns.
KBCT Compared to Traditional Modalities
The Koning Breast CT will dramatically improve the way clinicians visualize and evaluate breast tissue, mitigating patient discomfort and increasing survival rates. Future versions of our technology are expected to optimize early disease detection, diagnosis, intervention, and treatment.
Where You Can Find KBCT
KBCT is available in locations worldwide and has four locations in the U.S., including:
- Knoxville, TN
- Rochester, NY
- Tucson, AZ
Koning is changing the world’s perspective on breast imaging and has a vision to create a revolution in medical imaging through our advanced Computed Tomography technology. The power, versatility, and lower cost of Koning Breast CT will serve as a viable substitute for many traditional imaging applications.
Contact us today to learn more about the Koning difference and how KBCT simplifies existing workflows, saves time, reduces recalls, and improves efficacy, giving providers and patients an improved way of breast imaging.
The Future of 3D Breast Imaging
Breast imaging has evolved significantly, but the underlying goal remains the same: give physicians better information while making the process as effective and manageable as possible for patients.
Dedicated Breast CT represents one approach to that evolution.
True three-dimensional imaging allows clinicians to evaluate breast anatomy without relying on conventional breast compression. Rapid acquisition helps support practical clinical workflows, while additional capabilities such as contrast enhancement and image-guided procedures expand the potential applications of the technology.
As breast imaging continues to advance, technologies will increasingly be evaluated across several dimensions at once: image quality, diagnostic information, patient comfort, radiation exposure, workflow efficiency and cost.
Koning’s vision is to advance medical imaging through dedicated Computed Tomography technology that addresses these needs while giving physicians another tool for evaluating breast health.
For patients, the most noticeable difference may be simple: detailed breast imaging without painful compression.
For providers, the difference is the ability to work with a true three-dimensional dataset designed specifically for breast imaging.
Contact Koning to learn more about KBCT, available locations, clinical applications, and how dedicated Breast CT can fit into existing breast imaging workflows.
References:
- National Cancer Institute — SEER Cancer Statistics Review, 1975–2013
SEER Cancer Statistics Review, 1975–2013
This is the official NCI/SEER archive for the Howlader et al. reference. - Moss et al. — Effect of Mammographic Screening From Age 40 Years on Breast Cancer Mortality
PubMed — Lancet Randomized Controlled Trial
This is the PubMed record for the 2006 Lancet study, including the DOI and full citation details.
